LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites

Carcinogenesis

Volumn 30, Issue 3, 2009, Pages 457-465

  Komachi, Mayumi ^a   Tomura, Hideaki ^a   Malchinkhuu, Enkhzol ^a   Tobo, Masayuki ^a   Mogi, Chihiro ^a   Yamada, Takayuki ^a   Kimura, Takao ^b   Kuwabara, Atsushi ^b   Ohta, Hideo ^c   Im, Doon Soon ^d   Kurose, Hitoshi ^e   Takeyoshi, Izumi ^a   Sato, Koichi ^a   Okajima, Fumikazu ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KIRIN BREWERY CO LTD   (Japan)

^d Pusan National University   (South Korea)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; KI 16425; LP 105; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR AGONIST; MATRIGEL; PERTUSSIS TOXIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 3 (4 (4 ((1 (2 CHLOROPHENYL)ETHOXY)CARBONYL AMINO) 3 METHYL 5 ISOXAZOLYL) BENZYLSULFANYL) PROPANOIC ACID; 3-(4-(4-((1-(2-CHLOROPHENYL)ETHOXY)CARBONYL AMINO)-3-METHYL-5-ISOXAZOLYL) BENZYLSULFANYL) PROPANOIC ACID; COLLAGEN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; ISOXAZOLE DERIVATIVE; LAMININ; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; PROPIONIC ACID DERIVATIVE; PROTEOGLYCAN;

ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CANCER INVASION; CELL MOTION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ASCITES; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN; DRUG COMBINATIONS; EPIDERMAL GROWTH FACTOR; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; ISOXAZOLES; LAMININ; LYSOPHOSPHOLIPIDS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PERTUSSIS TOXIN; PROPIONIC ACIDS; PROTEOGLYCANS; RECEPTORS, LYSOPHOSPHATIDIC ACID; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING;

EID: 62349115729     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp011     Document Type: Article

References (44)

1. Vogel,I. et al. (2001) Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch., 439, 109-117.
2. Yoshida,T. et al. (2004) Development of gene therapy to target pancreatic cancer. Cancer Sci., 95, 283-289.
3. Hanahan,D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
4. Keleg,S. et al. (2003) Invasion and metastasis in pancreatic cancer. Mol. Cancer, 2, 14.
5. Ishii,I. et al. (2004) Lysophospholipid receptors: Signaling and biology. Annu. Rev. Biochem., 73, 321-354.
6. Meyer zu Heringdorf,D. et al. (2007) Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim. Biophys. Acta, 1768, 923-940.
7. Choi,J.W. et al. (2008) Biological roles of lysophospholipid receptors revealed by genetic null mice: An update. Biochim. Biophys. Acta, 1781, 531-539.
8. Westermann,A.M. et al. (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann. Oncol., 9, 437-442.
9. Xia,P. et al. (1998) Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc. Natl Acad. Sci. USA, 95, 14196-14201.
10. Yamada,T. et al. (2004) Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J. Biol. Chem., 279, 6595-6605.
11. Mills,G.B. et al. (2003) The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer, 3, 582-591.
12. Moolenaar,W.H. et al. (2004) The ins and outs of lysophosphatidic acid signaling. Bioessays, 26, 870-881.
13. Murph,M. et al. (2006) Of spiders and crabs: The emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin. Cancer Res., 12, 6598-6602.
14. Ohta,H. et al. (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol., 64 994-1005.
15. Zheng,Y. et al. (2001) Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J. Immunol., 166, 2317-2322.
16. Shida,D. et al. (2003) Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res., 63, 1706-1711.
17. Malchinkhuu,E. et al. (2005) Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells. Oncogene, 24, 6676-6688.
18. Hama,K. et al. (2004) Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J. Biol. Chem., 279, 17634-17639.
19. Ren,J. et al. (2006) Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res., 66, 3006-3014.
20. Sato,K. et al. (2005) Identification of autotaxin as a neurite retractioninducing factor of PC12 cells in cerebrospinal fluid and its possible sources. J. Neurochem., 92, 904-914.
21. Tobo,M. et al. (2007) Previously postulated "ligand-independent" signaling of GPR4 is mediated through proton-sensing mechanisms. Cell. Signal., 19, 1745-1753.
22. Malchinkhuu,E. et al. (2008) S1P(2) receptors mediate inhibition of glioma cell migration through Rho signaling pathways independent of PTEN. Biochem. Biophys. Res. Commun., 366, 963-968.
23. Tomura,H. et al. (2008) Cyclooxygenase-2 expression and prostaglandin E2 production in response to acidic pH through OGR1 in a human osteoblastic cell line. J. Bone Miner. Res., 23, 1129-1139.
24. Arai,K. et al. (2003) Differential requirement of G alpha12, G alpha13, G alphaq, and G beta gamma for endothelin-1-induced c-Jun NH2-terminal kinase and extracellular signal-regulated kinase activation. Mol. Pharmacol., 63, 478-488.
25. Virag,T. et al. (2003) Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol. Pharmacol., 63, 1032-1042.
26. Takuwa,Y. et al. (2008) Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim. Biophys. Acta, 1781, 483-488.
27. Kurose,H. (2003) Galpha12 and Galpha13 as key regulatory mediator in signal transduction. Life Sci., 74, 155-161.
28. Sugimoto,N. et al. (2006) Rho-dependent, Rho kinase-independent inhibitory regulation of Rac and cell migration by LPA1 receptor in Giinactivated CHO cells. Exp. Cell Res., 312, 1899-1908.
29. Jaganathan,B.G. et al. (2007) Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells, 25, 1966-1974.
30. Evers,E.E. et al. (2000) Rho family proteins in cell adhesion and cell migration. Eur. J. Cancer, 36, 1269-1274.
31. Sahai,E. et al. (2002) RHO-GTPases and cancer. Nat. Rev. Cancer 2, 133-142.
32. Raftopoulou,M. et al. (2004) Cell migration: Rho GTPases lead the way. Dev. Biol., 265, 23-32.
33. Sugimoto,N. et al. (2003) Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol. Cell. Biol., 23, 1534-1545.
34. Arikawa,K. et al. (2003) Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J. Biol. Chem., 278, 32841-32851.
35. Lepley,D. et al. (2005) The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res., 65, 3788-3795.
36. Sanchez,T. et al. (2005) PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc. Natl Acad. Sci. USA 102, 4312-4317.
37. Takashima,S. et al. (2008) G12/13 and Gq mediate S1P2-induced inhibition of Rac and migration in vascular smooth muscle in a manner dependent on Rho but not Rho kinase. Cardiovasc. Res., 79, 689-697.
38. Ortiz-Lopez,L. et al. (2008) ROCK-regulated cytoskeletal dynamics participate in the inhibitory effect of melatonin on cancer cell migration. J. Pineal Res., 46, 15-21.
39. Tabu,K. et al. (2007) Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA. Mol. Cancer Res., 5, 1099-1109.
40. Li,Z. et al. (2006) Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol. Cell. Biol., 26, 4240-4256.
41. Li,Z. et al. (2006) Cyclin D1 functions in cell migration. Cell Cycle, 5, 2440-2442.
42. Salhia,B. et al. (2005) Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res., 65, 8792-8800.
43. Gottig,S. et al. (2006) Role of the monomeric GTPase Rho in hematopoietic progenitor cell migration and transplantation. Eur. J. Immunol., 36, 180-189.
44. Boucharaba,A. et al. (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA, 103, 9643-9648.